Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease - ScienceDirect
ICS/LABA/LAMA per la BPCO è stata approvata in Europa • NCF
GOLD COPD DOCUMENT 2023: a brief update for practicing cardiologists | Clinical Research in Cardiology
A Review of the 2019 GOLD Guidelines for COPD
Wirkstoffkombination für COPD-Patienten: Erstattungsbetrag für Anoro vereinbart
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease - ScienceDirect
Pharmaceuticals | Free Full-Text | Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease
Kombinationspräparate bei COPD und Asthma - 03 - 2018 - Heftarchiv - AMT
Real World Impact | SPIRIVA® RESPIMAT® (tiotropium bromide)
Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine
Neue Dreifachkombi bei COPD | PZ – Pharmazeutische Zeitung
TRELEGY for COPD | TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol)